367-02-012 ISMRM Abstract

Early Metabolic Imaging Biomarkers of Pirtobrutinib Response in Mantle Cell Lymphoma by Magnetic Resonance Spectroscopy

Primary: Preclinical Animal & in vitro MR - Biology, Models, Methods

Secondary: Preclinical Animal & in vitro MR - Small Animals

367-02-012 · Cancer Detection and Therapies · Monday, 11 May, 9:15 AM–10:10 AM · Digital Posters Row H

Keywords: 1H and 31P Magnetic resonance spectroscopy (MRS) Mantle cell lymphoma (MCL) Brutons Tyrosine Kinase (BTK) Monitoring Therapeutic Response Metabolic biomarkers

Accepted

Pradeep Kumar Gupta ¹, David Rushmore², Skyler Nova¹, Fernando Arias-Mendoza^1,3, David Nelson¹, Mariusz A Wasik², Kavindra Nath¹

¹University of Pennsylvania, Philadelphia, United States of America

²Department of Pathology, Fox Chase Cancer Center, Philadelphia, United States of America

³Advanced Imaging Research, Inc., Cleveland, United States of America

Presenting Author: Pradeep Kumar Gupta

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Ibrahim S, Pham N, Sahni A, et al. Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncology.1-11. doi: 10.1080/14796694.2025.2567834. [doi]

2. Nath K, Gupta PK, Wasik MA. Emerging Role of Functional Magnetic Resonance Spectroscopy (MRS) to Monitor Response to Kinase Inhibitors in Cancer. Adv Cancer Res Clin Imaging. 2024;4(3). Epub 20240705. doi: 10.33552/acrci.2024.04.000587. PubMed PMID: 39161974; PMCID: PMC11332593. [doi] [pmid]

3. Nath K, Gupta PK, Wang S, et al. Magnetic resonance spectroscopy-based detection of response to therapy targeting glutaminolysis in lymphoma. Blood Neoplasia. 2025;2(3):100105. Epub 20250415. doi: 10.1016/j.bneo.2025.100105. PubMed PMID: 40575077; PMCID: PMC12197994. [doi] [pmid]

4. Nath K, Gupta PK, Basappa J, et al. Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition. J Transl Med. 2024;22(1):622. Epub 20240704. doi: 10.1186/s12967-024-05371-9. PubMed PMID: 38965536; PMCID: PMC11225145. [doi] [pmid]

5. Gupta PK, Li LZ, Singh DK, et al. MRS and Optical Imaging Studies of Therapeutic Response to Combination Therapy Targeting BRAF/MEK in Murine Melanomas. Acad Radiol. 2025. Epub 20250220. doi: 10.1016/j.acra.2025.01.035. PubMed PMID: 39984334. [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/367-02-012